<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02103283</url>
  </required_header>
  <id_info>
    <org_study_id>DME01RV</org_study_id>
    <nct_id>NCT02103283</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)</brief_title>
  <official_title>Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Center-Involved Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>River Vision Development Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>River Vision Development Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular
      Edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth
      Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Center-Involved
      Diabetic Macular Edema (DME).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of RV001in subjects with Diabetic Macular Edema</measure>
    <time_frame>Change from Baseline to Week 9</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects with adverse events, serious adverse events and early discontinuations due to adverse events. Number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of RV001in subjects with Diabetic Macular Edema</measure>
    <time_frame>Change from Baseline to Week 9</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pharmacodynamic measure includes change in Optical Coherence Tomography, Fluorescein Angiography and Stereoscopic color funds photos findings.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Teprotumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teprotumumab</intervention_name>
    <description>Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions</description>
    <arm_group_label>Teprotumumab</arm_group_label>
    <other_name>RV 001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus with Hemoglobin A1c &lt;8%

          -  IGF 1 in serum &gt; 145ng/mL

          -  Women of child-bearing potential must have negative pregnancy test and be willing and
             able to use two different methods of contraception, one of which must be oral
             contraceptive or depot formulation. Males must be surgically sterile or agree to use
             barrier contraception

          -  DME of less than 12 months with retinal thickening due to DME involving the center of
             the macula

          -  Non-proliferative diabetic retinopathy of moderate severity equivalent to Electronic
             Early Treatment Diabetic Retinopathy Study (ETDRS) level 47 or below

          -  Best corrected electronic ETDRS letter score &lt; 78 and &gt; 24

          -  DME on Optical Coherence Tomography &gt; 250 Î¼m

        Exclusion Criteria:

          -  Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication
             greater than 15% in the previous 60 days.

          -  Significant renal disease, myocardial infarction, stroke, transient ischemic attack,
             acute congestive heart failure

          -  Blood pressure &gt; 180/110

          -  Systemic anti-vascular endothelial growth factor (VEGF) treatment within four months
             prior to enrollment

          -  History of pan retinal photocoagulation within four months prior to enrollment

          -  History of ocular surgery within four months prior to enrollment

          -  History of systemic treatment with corticosteroids within 3 months prior to
             enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Cousins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Ophthalmology Duke Eye Center Duke University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Vitreous Associates Beverley Hills, California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathie Gabriel, BSN, MFT</last_name>
    <phone>610-937-1932</phone>
    <email>kcgabriel2@verizon.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>David S Boyer</name>
      <address>
        <city>Beverley Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
